- Business Wire•35 minutes ago
Pfizer Inc. today announced the pricing of $1,065,000,000 aggregate principal amount of 4.20% notes due 2047. This offering is expected to be sold to professional institutional investors in Taiwan, with application to be made to list the notes on the Taipei Exchange.
- Investopedia•3 hours ago
Lung cancer drug Zykadia got priority review status and breakthrough designation from the FDA.
- Moody's•5 hours ago
New York, February 24, 2017-- Moody's Investors Service assigned an A1 rating to new senior unsecured notes being offered by Pfizer Inc.. The rating outlook is stable. There are no changes to Pfizer's ...
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||33.99 - 34.35|
|52 Week Range||28.74 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.01|
|Dividend & Yield||1.28 (3.81%)|
|1y Target Est||N/A|